When Is Targeted 308 nm Excimer Phototherapy Appropriate for Vitiligo?

For localized vitiligo, treating individual lesions with targeted phototherapy may be more practical than exposing a much larger area of skin. When depigmentation is widespread, narrowband UVB (NB-UVB), typically centered around 311–313 nm, may be more practical because it can cover larger treatment areas.

A 308 nm excimer laser or light system delivers UVB to selected lesions. Whether targeted treatment is appropriate depends on lesion distribution, anatomical site, previous treatment response and the patient's clinical circumstances.

When Is Targeted Phototherapy Appropriate?

The Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan describe targeted excimer laser or light therapy as an option for lesions affecting less than 5% of body surface area that have not responded adequately to topical corticosteroids or tacrolimus. This is a recommendation from a specific national guideline, not a universal threshold for treatment eligibility. [1]

Lesion location also affects treatment expectations. Facial and neck lesions generally have a more favorable repigmentation outlook than lesions on the hands and feet. White hairs within affected areas may indicate a less favorable response because they can reflect loss of pigment-producing cells in the hair follicles. [2]

For patients with a limited number of accessible lesions, targeted treatment can reduce irradiation of surrounding unaffected skin. With numerous lesions scattered across a larger area, treating each site individually may become less practical.

308 nm Excimer Laser vs NB-UVB: What Does the Evidence Show?

A randomized, single-blind study compared localized 308 nm excimer light with targeted 311 nm NB-UVB in 36 pairs of symmetrical vitiligo lesions. After 48 treatment sessions, the excimer-treated lesions showed greater improvement in Vitiligo Area Scoring Index (VASI). Excellent repigmentation was achieved in 25% of excimer-treated lesions, compared with 13.89% of lesions treated with targeted NB-UVB. The excimer-treated lesions also reached 25% repigmentation in fewer sessions on average: 19.42 sessions versus 26.25 sessions. [3]

These results favor excimer light under the protocol studied. However, the trial was small and evaluated paired lesions, so the findings do not establish that every excimer system will outperform NB-UVB in routine practice.

A 2025 retrospective study compared targeted NB-UVB, 308 nm excimer laser and 308 nm excimer lamp therapy. At 3–6 months, 76–100% repigmentation was observed in 42.4% of lesions treated with NB-UVB, 17.6% treated with excimer laser and 29.4% treated with excimer lamp. The differences in efficacy were not statistically significant, while adverse events were more frequent in the excimer lamp group. [4]

The studies examined different treatment settings and used different designs. The randomized trial found an advantage for excimer light in its specific comparison, whereas the retrospective study did not establish a statistically significant efficacy difference among its three groups. Neither result justifies ranking all devices by modality alone.

NB-UVB remains an important option for widespread or progressive non-segmental vitiligo, as reflected in the Japanese guidelines. [1]

What Should Guide Treatment Selection?

Lesion distribution. Targeted phototherapy is practical when a limited number of lesions require treatment. NB-UVB may be more suitable when multiple or widespread areas need coverage.

Anatomical site. Facial lesions generally respond more favorably than lesions on the hands and feet. Repigmentation can vary between body sites, even within the same patient.

Previous treatment and disease activity. Targeted 308 nm phototherapy may be considered for localized lesions that have not responded adequately to topical treatment. Widespread or rapidly progressive disease may require a broader management plan.

Dose, frequency and treatment duration should follow the clinician's assessment, applicable guidance and the device's validated instructions. Published study protocols should not automatically be transferred to other devices or patients.

Choosing a 308 nm Excimer System for Clinical Use

For clinics treating localized vitiligo, equipment selection should reflect the lesion sizes commonly encountered and the clinic's treatment workflow.

KernelMed's KN-5000D product information lists selectable dose and time modes, a built-in minimum erythema dose (MED) testing function, shading sheets for different treatment areas, and treatment-record management. The specified light source is 308 nm XeCl excimer light. These features describe the system's functions rather than demonstrating superior clinical outcomes.

Product details:
https://www.kernelmedint.com/product/308nm-excimer-laser-system-dermatology-kn-5000d-vitiligo-targeted-treatment

FAQ

1.Is an excimer laser effective for vitiligo?

Clinical studies support 308 nm excimer laser or light therapy for selected patients, particularly those with localized lesions. Repigmentation varies with lesion location, disease characteristics and treatment protocol.

2.Is a 308 nm excimer laser better than NB-UVB?

The evidence does not establish one approach as universally superior. Targeted excimer phototherapy is suited to selected localized lesions, while NB-UVB is an important option when more extensive areas need treatment.

3. Does 308 nm excimer phototherapy work on the hands and feet?

Repigmentation can be more difficult on acral areas, including the hands and feet, than on the face and neck. Targeted phototherapy may still be considered for selected lesions, but patients should understand that response may be limited and can differ from that seen at other body sites.

4. How many sessions are needed to see repigmentation?

There is no single session count that applies to every patient. Response depends on the anatomical site, disease characteristics, treatment protocol and individual response. In the randomized comparison cited above, the excimer-treated lesions reached 25% repigmentation in an average of 19.42 sessions, compared with 26.25 sessions for targeted NB-UVB. These figures describe that study's results, not a guaranteed treatment schedule.

5. Can excimer phototherapy be combined with topical treatment?

Targeted 308 nm phototherapy may be used as part of a clinician-directed treatment plan that also includes topical therapy. The appropriate combination depends on the patient's disease characteristics, previous response and treatment goals. The evidence for one combination should not automatically be generalized to all protocols or patients.

References

[1] Tanemura A, Oiso N, Okamura K, et al. Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025). Journal of Dermatology. 2026;53(8)–e638.

[2] Seneschal J, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force—Part 2: Specific treatment recommendations. Journal of the European Academy of Dermatology and Venereology. 2023;37(11):2185–2195.

[3] Poolsuwan P, Churee C, Pattamadilok B. Comparative efficacy between localized 308-nm excimer light and targeted 311-nm narrowband ultraviolet B phototherapy in vitiligo: A randomized, single-blind comparison study. Photodermatology, Photoimmunology & Photomedicine. 2021;37(2):123–130.

[4] Tantivithiwate T, Chaiyabutr C, Wongpraparut C, et al. Comparative efficacy and safety of targeted narrowband ultraviolet B, 308-nm excimer laser, and 308-nm excimer lamp in vitiligo: A retrospective study. Journal of Dermatological Treatment. 2025;36(1):2514637.